G. Pompilio, A. Morabito, D. L. Cortinovis, and D. Integlia, “Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations”, Grhta, vol. 9, no. 1, pp. 22–29, Jan. 2022.